Table 1.
Patient demographics
| Characteristic | No. of patients | For EFS | For OS | |||
|---|---|---|---|---|---|---|
| IV infusion | IA infusion | Pua | Pmb | Pu | Pm | |
| Total | 51 | 48 | 0.233 | N/A | 0.176 | N/A |
| Gender | 0.057 | N/A | 0.133 | N/A | ||
| Male | 26 (51.0%) | 34 (70.8%) | ||||
| Female | 25 (49.0%) | 14 (29.2%) | ||||
| Agec | 0.349 | N/A | 0.145 | N/A | ||
| Child | 16 (31.4%) | 10 (20.8%) | ||||
| Adolescent | 16 (31.4%) | 18 (37.5%) | ||||
| Adult | 19 (37.2%) | 20 (41.7%) | ||||
| Pathological subtypes | 0.395 | N/A | 0.564 | N/A | ||
| Chondroblastic | 7 (13.7%) | 10 (20.8%) | ||||
| Common type without chondroblastic | 37 (72.5%) | 36 (75.0%) | ||||
| Telangiectatic type | 4 (7.8%) | 1 (2.1%) | ||||
| Small cell type | 2 (3.9%) | 1 (2.1%) | ||||
| High-grade surface type | 1 (2.0%) | 0 (0%) | ||||
| Locations | 0.412 | N/A | 0.951 | N/A | ||
| Distal femur | 23 (45.1%) | 33 (68.8%) | ||||
| Proximal tibia | 10 (19.6%) | 15 (31.2%) | ||||
| Proximal femur | 2 (3.9%) | 0 (0%) | ||||
| Proximal humerus | 12 (23.6%) | 0 (0%) | ||||
| Others | 4 (7.8%) | 0 (0%) | ||||
| Stage (Ennecking)d | 0.003 | 0.003 | 0.000 | 0.000 | ||
| IIB | 35 (68.6%) | 43 (89.6%) | ||||
| III | 16 (31.4%) | 5 (10.4%) | ||||
| Surgical procedures | 0.223 | N/A | 0.692 | N/A | ||
| Limb salvage | 49 (96.1%) | 48 (100.0%) | ||||
| Amputation | 2 (3.9%) | 0 (0%) | ||||
| Surgical margins | 0.023 | 0.135 | 0.024 | 0.283 | ||
| R0 | 37 (72.5%) | 43 (89.6%) | ||||
| R1 | 9 (17.6%) | 5 (10.4%) | ||||
| N/A | 5 (9.8%) | 0 (0%) | ||||
| Preoperative chemotherapy time interval | 0.272 | N/A | 0.244 | N/A | ||
| Less than 8 weeks | 21 (41.2%) | 10 (20.8%) | ||||
| More than 8 weeks | 30 (58.8%) | 38 (79.2%) | ||||
| Preoperative chemotherapy protocol | 0.846 | N/A | 0.931 | N/A | ||
| Without IFO | 13 (25.5%) | 10 (20.8%) | ||||
| With IFO | 38 (74.5%) | 38 (79.2%) | ||||
| Perfusion time | 0.795 | N/A | 0.454 | N/A | ||
| 3 hrs | 0 (0%) | 19 (39.6%) | ||||
| 6 hrs | 0 (0%) | 29 (60.4%) | ||||
| Histological response | 0.041 | 0.153 | 0.034 | 0.037 | ||
| Goode | 20 (39.2%) | 26 (54.2%) | ||||
| Poor | 31 (60.8%) | 22 (45.8%) | ||||
Notes: aProbability of a significance (COX univariate analysis); bProbability of a significance (COX multivariate analysis); cGroups defined according to Collins et al:20 child (0–12 for males and 0–11 for females), adolescent (13–17 for males and 12–16 for females), and adult (≥18 for males and ≥17 for females); dAccording to Enneking et al;24 eUpon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as Picci et al,23 tumor histopathological response grading system (Huvos classification), where we defined an equal to or more than 90% tumor necrosis rate as a good histological response and less than 90% as a poor response.
Abbreviations: EFS, event-free survival; IA, intra-arterial; IFO, Ifosfamide; IV, intravenous; N/A, not available; OS, overall survival.